Sanofi $SNY Stock Acquired by Boston Partners

Boston Partners increased its position in Sanofi (NASDAQ:SNY – Free Report) by 4.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 3,999,818 shares of the company’s stock after buying an additional 154,974 shares during the quarter. Boston Partners’ holdings in Sanofi were worth $164,837,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its holdings in Sanofi by 2.7% in the 2nd quarter. Allworth Financial LP now owns 9,233 shares of the company’s stock worth $394,000 after buying an additional 243 shares in the last quarter. Euro Pacific Asset Management LLC grew its stake in shares of Sanofi by 0.6% during the third quarter. Euro Pacific Asset Management LLC now owns 46,121 shares of the company’s stock valued at $1,902,000 after acquiring an additional 253 shares in the last quarter. Rothschild Investment LLC grew its stake in shares of Sanofi by 7.8% during the third quarter. Rothschild Investment LLC now owns 3,847 shares of the company’s stock valued at $159,000 after acquiring an additional 277 shares in the last quarter. Focused Alpha LLC increased its position in shares of Sanofi by 4.5% during the third quarter. Focused Alpha LLC now owns 6,553 shares of the company’s stock worth $270,000 after acquiring an additional 281 shares during the last quarter. Finally, Intrua Financial LLC increased its position in shares of Sanofi by 6.4% during the third quarter. Intrua Financial LLC now owns 5,100 shares of the company’s stock worth $210,000 after acquiring an additional 309 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. DZ Bank reissued a “buy” rating on shares of Sanofi in a report on Friday, July 31st. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Berenberg Bank reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Finally, BNP Paribas Exane raised shares of Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 price target for the company in a research report on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $53.00.

View Our Latest Stock Report on SNY

Latest Sanofi News

Here’s some of the latest news about SNY:

  • Positive Sentiment: Sanofi selected Jacobs to help deliver a new insulin manufacturing facility in Frankfurt, Germany. The project could support production capacity over time, although it also entails investment. Article: New insulin manufacturing facility
  • Neutral Sentiment: Reports say Sanofi is weighing a possible acquisition of Insmed, a biotech company with a market value of about $26 billion. A deal could add to Sanofi’s pipeline, but no transaction terms or confirmation were reported, leaving the potential cost and strategic impact uncertain. Article: Sanofi weighs potential Insmed takeover
  • Negative Sentiment: Investors bought 2,521 put options on SNY, about 35% above the average daily volume. This may indicate increased hedging or bearish positioning, though options activity alone does not establish market direction.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $46.06 on Friday. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a fifty-two week low of $39.07 and a fifty-two week high of $50.60. The firm has a 50-day simple moving average of $43.00 and a 200 day simple moving average of $44.39. The company has a market cap of $111.67 billion, a PE ratio of 22.80, a P/E/G ratio of 1.29 and a beta of 0.31.

Sanofi (NASDAQ:SNY – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. Sanofi’s revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the company posted $2.91 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 5.07 EPS for the current year.

About Sanofi

(Free Report)

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.